thumb
November 22, 2021

Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

Today, Biogen and Eisai announced that the Journal of the American Medical Association (JAMA) Neurology published a peer-reviewed paper about findings around amyloid-related imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM (aducanumab-avwa).

thumb
January 13, 2021

Biogen to Report Fourth Quarter and Full Year 2020 Financial Results February 3, 2021

Cambridge, Mass. — Biogen Inc. (Nasdaq:BIIB) today announced it will report fourth quarter and full year 2020 financial results Wednesday, February 3, 2021, before the financial markets open.  Following the release of the financials, the Company will host a live webcast with Biogen management at

thumb
January 11, 2021

Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone

The study aims to identify digital biomarkers to help monitor cognitive performance and health including potentially detecting mild cognitive impairment, an early indicator of certain forms of dementia such as Alzheimer’s disease  Cognitive health — the ability to think clearly, to learn and to

thumb
January 8, 2021

Biogen to Participate in Webinar with Alzheimer's Disease International on January 14, 2021

Cambridge, Mass. – Biogen (Nasdaq: BIIB) today announced it will participate in a webinar with Alzheimer’s Disease International (ADI) including a presentation related to its Alzheimer’s disease investigational therapy, aducanumab, as well as a live question and answer (Q&A) session.

thumb
January 8, 2021

Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)

The global Phase 4 RESPOND study will evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical response to Zolgensma Clinical and real-world experience have reported that some patients previously treated with Zolgensma have also been treated with SPINRAZA 1,2,3,4 Biogen

thumb
January 4, 2021

Biogen to Present at the 39th Annual J.P. Morgan Healthcare Conference

Cambridge, MA, - - Biogen Inc .  (Nasdaq: BIIB) announced today that it will present at the virtual 39th Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 11, 2021 at 10:00 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at

thumb
December 21, 2020

The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis

PLEGRIDY is now approved in the European Union for intramuscular injection, offering individuals with relapsing multiple sclerosis (MS) a differentiated, reliable treatment option combining safety and efficacy to help optimize their treatment experience with significantly reduced injection site

thumb
December 9, 2020

Biogen Files New Drug Application for Aducanumab in Japan

If approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimer’s disease Aducanumab is now under regulatory review in Japan, Europe and the United States CAMBRIDGE, Mass. and TOKYO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Today, Biogen (Nasdaq: BIIB) and Eisai,

thumb
November 27, 2020

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders

Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S. Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S . , excluding rights to zuranolone in Japan, Taiwan and South Korea Sage

thumb
November 18, 2020

Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)

INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application for SB11, a proposed biosimilar

thumb
November 16, 2020

Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership

Biogen earns top scores on areas including access to medicine, talent attraction, innovation management and climate performance and reporting In 2013 Biogen became the 1 st U.S. biotech company to appear on the DJSI World Index 2020 marks the 8 th consecutive year that Biogen was listed among top